Immuno-oncological effects of the α2-adrenoceptor agonist dexmedetomidine
The α2-adrenergic receptor agonist dexmedetomidine (DEX) exerts context-dependent antitumor effects, with its efficacy influenced by dose, immune cell involvement and combination with immune checkpoint inhibitors. It will be important to understand to which extent DEX and other α2-adrenergic agonist...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2542334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|